Abstract: Objective: To explore the clinical toxicities and anti-tumor effects of FTQ combined with cisplatin on patients with advanced gastric cancer. Methods: One hundred and ninety one patients were divided into two groups. In the observation group, FTQ (80 mg/m²) was administered orally twice per day for 14 consecutive days in each cycle and cisplatin (25 mg/m²) was administered on the 1st to the 3rd day of every cycle (21 days for each cycle). Three cycles were performed. The control group also received 3 cycles of treatment. TS-1(80 mg/m²) was administered three times per day for 14 consecutive days in each cycle and cisplatin was administered in the same way as in the observation group. Results: The overall response rate was 31.31% in the observation group and 6.52% in the control group. The rate of improvement was 53.54% in the observation group and 23.91% in the control group. The clinical benefit rate was 90.91% in the observation group and 76.09% in the control group. The two groups presented with similar incidence rate of leucopenia and thrombocytopenia. But the incidence rate of vomiting was higher in the control group than that in the observation group. Conclusion: FTQ combined with cisplatin is well tolerated and can be generally administered to patients with advanced gastric cancer.